AZD3632 clinical trials

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

This study is looking into a new drug, AZD3632, for certain blood cancers like leukaemia and myelodysplastic syndromes. It aims to check its safety, how well it works, and how the body handles it, both on its own and with another medicine.